Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Chief Financial Officer and VP | February 14, 2020 | February 19, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Spyre Therapeutics, Inc.
Report date February 14, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2030-02-13 | Direct | 126,000 |
Reported balance
After 2020-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-14 · Grant · Acquired 126,000 · Balance 126,000 F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 14, 2020, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 14, 2020, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Day One Biopharmaceuticals, Inc.
Report date April 23, 2026 · Filed April 23, 2026
Section 16 reporting ended · disclosed 2026-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Disposition to issuer · Disposed 312,025 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2031-05-25 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-23 · Disposition to issuer · Disposed 497,667 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2032-01-17 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-23 · Disposition to issuer · Disposed 151,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5: The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2033-01-16 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-23 · Disposition to issuer · Disposed 116,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F6: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-01-04 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-23 · Disposition to issuer · Disposed 162,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F7: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2035-01-14 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-23 · Disposition to issuer · Disposed 162,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F8: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2036-01-29 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-23 · Disposition to issuer · Disposed 188,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F9: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-23 · Disposition to issuer · Disposed 6,750 · Balance 0 F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F11: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-23 · Disposition to issuer · Disposed 46,375 · Balance 0 F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F11: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-23 · Disposition to issuer · Disposed 72,875 · Balance 0 F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F11: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-04-23 · Disposition to issuer · Disposed 118,125 · Balance 0 F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F13: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.
F3: The options are fully vested.
F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.
F5: The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F6: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F7: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F8: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F9: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F11: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.
F13: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2024 Filed Feb 20, 2024 23:36 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-004469 · form4-02202024_110257.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 00:29 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantRestricted Stock Units · Derivative | 106,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001296 · doc4.xml · derivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,000 Underlying: Common Stock · 106,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 00:29 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 162,000 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001209191-24-001296 · doc4.xml · derivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,000 Underlying: Common Stock · 162,000 shares Expires 2034-01-04 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 23:33 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 956 | $11.69 | $11,175.64 |
DisclosureSEC source: 0001209191-23-055896 · doc4.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,170 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 23:33 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055896 · doc4.xml · derivative · entry 5 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 23:33 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Units · Derivative | 1,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055896 · doc4.xml · derivative · entry 4 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 1,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 23:33 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-055896 · doc4.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 23:33 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-055896 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| August 17, 2023 Filed Aug 17, 2023 23:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 922 | $13.86 | $12,778.92 |
DisclosureSEC source: 0001209191-23-046430 · doc4.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,501 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 23:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046430 · doc4.xml · derivative · entry 5 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,250 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 23:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Units · Derivative | 1,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046430 · doc4.xml · derivative · entry 4 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,375 Underlying: Common Stock · 1,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 23:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046430 · doc4.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 23:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046430 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| May 16, 2023 Filed May 17, 2023 22:36 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 955 | $13.12 | $12,531.80 |
DisclosureSEC source: 0001209191-23-030395 · doc4.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,798 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document |
| May 15, 2023 Filed May 17, 2023 22:36 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030395 · doc4.xml · derivative · entry 5 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 15, 2023 Filed May 17, 2023 22:36 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Units · Derivative | 1,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030395 · doc4.xml · derivative · entry 4 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 1,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 15, 2023 Filed May 17, 2023 22:36 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-030395 · doc4.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| May 15, 2023 Filed May 17, 2023 22:36 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-030395 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 22:01 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 9,377 | $20.03 | $187,790.37 |
DisclosureSEC source: 0001209191-23-011263 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,128 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 22:35 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 930 | $19.57 | $18,202.89 |
DisclosureSEC source: 0001209191-23-010823 · doc4.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,505 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:35 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010823 · doc4.xml · derivative · entry 5 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:35 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Units · Derivative | 1,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010823 · doc4.xml · derivative · entry 4 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,125 Underlying: Common Stock · 1,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:35 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-010823 · doc4.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:35 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-010823 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 20, 2023 Filed Jan 23, 2023 23:00 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 10,000 | $22.75 | $227,523.00 |
DisclosureSEC source: 0001209191-23-004485 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,810 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.48 to $23.08 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 2,313 shares of Common Stock acquired under the Issuer's employee stock purchase plan on November 15, 2021, and May 13, 2022. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantRestricted Stock Units · Derivative | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004045 · doc4.xml · derivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 116,000 | $0.00 Strike: $20.87 | $0.00 |
DisclosureSEC source: 0001209191-23-004045 · doc4.xml · derivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,000 Underlying: Common Stock · 116,000 shares Expires 2033-01-16 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 22:43 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 10,000 | $20.07 | $200,650.00 |
DisclosureSEC source: 0001209191-22-062486 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,497 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 23:46 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 300 | $21.39 | $6,417.00 |
DisclosureSEC source: 0001209191-22-058493 · doc4.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,497 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.35 to $21.43 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 23:46 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 9,700 | $20.74 | $201,152.78 |
DisclosureSEC source: 0001209191-22-058493 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,797 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.33 to $21.27 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 22:49 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 430 | $21.46 | $9,227.71 |
DisclosureSEC source: 0001209191-22-057645 · doc4.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,497 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. F3 · balance_after: Includes 1,151 shares of Common Stock acquired under the Issuer's employee stock purchase plan on November 16, 2022. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:49 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Units · Derivative | 1,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057645 · doc4.xml · derivative · entry 3 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 1,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award in quarterly installments on February 15th, May 15th, August 15th, and November 15th, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs will vest as to 1/12 of the total award in quarterly installments on February 15th, May 15th, August 15th, and November 15th, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:49 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-057645 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:49 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 10,000 | $20.03 | $200,313.00 |
DisclosureSEC source: 0001209191-22-055609 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,401 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.55 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:36 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 10,000 | $20.05 | $200,473.00 |
DisclosureSEC source: 0001209191-22-052763 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,401 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 23:54 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 1,394 | $23.80 | $33,175.39 |
DisclosureSEC source: 0001209191-22-048900 · doc4.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,401 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 15, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.7100 to $23.8500 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 23:54 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 8,606 | $23.16 | $199,308.94 |
DisclosureSEC source: 0001209191-22-048900 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,795 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 15, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.7100 to $23.6800 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 23:23 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 1,089 | $24.31 | $26,473.59 |
DisclosureSEC source: 0001209191-22-046482 · doc4.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,401 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the settlement of restricted stock units ("RSUs"). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 23:23 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Units · Derivative | 4,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046482 · doc4.xml · derivative · entry 3 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,875 Underlying: Common Stock · 4,125 shares Expires 2032-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award in quarterly installments on February 15th, May 15th, August 15th, and November 15th, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 23:23 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 4,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046482 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 21:20 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 10,000 | $20.05 | $200,541.00 |
DisclosureSEC source: 0001209191-22-044601 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,365 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 15, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.34 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 22:18 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 2,500 | $20.00 | $50,000.00 |
DisclosureSEC source: 0001209191-22-042766 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,365 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 15, 2021. Read SEC document |
| July 08, 2022 Filed Jul 12, 2022 23:31 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 1,416 | $20.00 | $28,320.00 |
DisclosureSEC source: 0001209191-22-041977 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,865 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 15, 2021. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 01:00 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 800 | $20.00 | $16,000.00 |
DisclosureSEC source: 0001209191-22-041410 · doc4.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,281 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| July 01, 2022 Filed Jul 7, 2022 01:00 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 1,479 | $20.00 | $29,580.00 |
DisclosureSEC source: 0001209191-22-041410 · doc4.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,081 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:30 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantRestricted Stock Units · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004205 · doc4.xml · derivative · entry 2 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2032-01-17 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award in quarterly installments on February 15th, May 15th, August 15th, and November 15th, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:30 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 151,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001209191-22-004205 · doc4.xml · derivative · entry 1 York Charles N II · CIK 0001655962 · COO, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,000 Underlying: Common Stock · 151,000 shares Expires 2032-01-17 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 22:15 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 126,000 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001567619-20-004319 · doc1.xml · derivative · entry 1 York Charles N II · CIK 0001655962 · Chief Financial Officer and VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 14, 2020, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 22:10 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 87,600 | $0.00 Strike: $8.36 | $0.00 |
DisclosureSEC source: 0001567619-19-005839 · doc1.xml · derivative · entry 1 York Charles N II · CIK 0001655962 · Chief Financial Officer and VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,600 Underlying: Common Stock · 87,600 shares Expires 2029-02-27 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 28, 2019, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 23:24 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 92,100 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0001140361-18-009666 · doc1.xml · derivative · entry 1 York Charles N II · CIK 0001655962 · Chief Financial Officer and VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,100 Underlying: Common Stock · 92,100 shares Expires 2028-02-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.